← Back to Search

Psychosocial Interventions for Schizophrenia

N/A

Recruiting

Research Sponsored by Beth Israel Deaconess Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 to 65

DSM-5 diagnosis of schizophrenia or schizoaffective or schizophreniform disorder

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measurement at 0, 6, 12 months

Awards & highlights

Study Summary

This trialwill measure how smell affects mental health treatment for people with schizophrenia, to better tailor interventions and help improve outcomes.

Who is the study for?

This trial is for individuals aged 18 to 65 with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. It's not suitable for those with severe substance use disorders, intellectual disabilities, or organic brain syndromes as per DSM-5 criteria.Check my eligibility

What is being tested?

The study aims to see if a person's sense of smell can predict who will benefit from social skills training and cognitive enhancement therapy in treating schizophrenia.See study design

What are the potential side effects?

Since the interventions are psychosocial rather than medical treatments like drugs or surgery, they may include discomfort during therapy sessions but do not have physical side effects typical of medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 65 years old.

Select...

I have been diagnosed with schizophrenia or a related disorder.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measurement at 0, 6, 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measurement at 0, 6, 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and measurement at 0, 6, 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Heinrich Quality of Life Scale

Change in Social Adjustment Scale II

Change in Social Skills Performance Assessment rating scale

Secondary outcome measures

Change in Managing Emotions subscale of the Meyer-Salovey-Caruso Emotional Intelligence Test (MSCEIT)

Change in NIH Toolbox® for Assessment of Neurological and Behavioral Function (NIH Toolbox)

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Cognitive Enhancement TherapyExperimental Treatment1 Intervention

CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.

Group II: Social Skills TrainingActive Control1 Intervention

The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cognitive Enhancement Therapy

2012

N/A

~160

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH

2,786 Previous Clinical Trials

2,689,651 Total Patients Enrolled

249 Trials studying Schizophrenia

89,319 Patients Enrolled for Schizophrenia

Beth Israel Deaconess Medical CenterLead Sponsor

837 Previous Clinical Trials

13,010,156 Total Patients Enrolled

21 Trials studying Schizophrenia

1,886 Patients Enrolled for Schizophrenia

Media Library

Cognitive Enhancement Therapy Clinical Trial Eligibility Overview. Trial Name: NCT05282186 — N/A

Schizophrenia Research Study Groups: Cognitive Enhancement Therapy, Social Skills Training

Schizophrenia Clinical Trial 2023: Cognitive Enhancement Therapy Highlights & Side Effects. Trial Name: NCT05282186 — N/A

Cognitive Enhancement Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05282186 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are seniors welcome to enroll in this research project?

"Out of the 216 similar clinical trials, this one specifically is only for patients aged 18-65."

Answered by AI

How many study subjects are enrolled in this research project?

"That is correct. The listing on clinicaltrials.gov says that the trial is ongoing and looking for 116 participants from a single site. The listing was first posted on May 1st, 2022 and was last updated on October 27th, 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

What the Nose Knows: Hedonic Capacity, Psychosocial Interventions and Outcomes in Schizophrenia

Raquelle Mesholam-Gately 2022. "What the Nose Knows: Hedonic Capacity, Psychosocial Interventions and Outcomes in Schizophrenia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05282186.

All > Schizophrenia